194 related articles for article (PubMed ID: 38781347)
1. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells.
Bulanova D; Akimov Y; Senkowski W; Oikkonen J; Gall-Mas L; Timonen S; Elmadani M; Hynninen J; Hautaniemi S; Aittokallio T; Wennerberg K
Sci Adv; 2024 May; 10(21):eadj1564. PubMed ID: 38781347
[TBL] [Abstract][Full Text] [Related]
2. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.
Brough R; Gulati A; Haider S; Kumar R; Campbell J; Knudsen E; Pettitt SJ; Ryan CJ; Lord CJ
Oncogene; 2018 Oct; 37(43):5701-5718. PubMed ID: 29915391
[TBL] [Abstract][Full Text] [Related]
3. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
[TBL] [Abstract][Full Text] [Related]
4. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Moens S; Zhao P; Baietti MF; Marinelli O; Van Haver D; Impens F; Floris G; Marangoni E; Neven P; Annibali D; Sablina AA; Amant F
Sci Rep; 2021 Feb; 11(1):3176. PubMed ID: 33542435
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
6. Acquired
Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
[TBL] [Abstract][Full Text] [Related]
7. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma.
Zoumpoulidou G; Alvarez-Mendoza C; Mancusi C; Ahmed RM; Denman M; Steele CD; Tarabichi M; Roy E; Davies LR; Manji J; Cristalli C; Scotlandi K; Pillay N; Strauss SJ; Mittnacht S
Nat Commun; 2021 Dec; 12(1):7064. PubMed ID: 34862364
[TBL] [Abstract][Full Text] [Related]
9. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q; Ba-Alawi W; Deblois G; Cruickshank J; Duan S; Lima-Fernandes E; Haight J; Tonekaboni SAM; Fortier AM; Kuasne H; McKee TD; Mahmoud H; Kushida M; Cameron S; Dogan-Artun N; Chen W; Nie Y; Zhang LX; Vellanki RN; Zhou S; Prinos P; Wouters BG; Dirks PB; Done SJ; Park M; Cescon DW; Haibe-Kains B; Lupien M; Arrowsmith CH
Nat Commun; 2020 Aug; 11(1):4205. PubMed ID: 32826891
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
11. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
[TBL] [Abstract][Full Text] [Related]
12. Cells Lacking the
Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
14. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
16. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
Robinson TJ; Liu JC; Vizeacoumar F; Sun T; Maclean N; Egan SE; Schimmer AD; Datti A; Zacksenhaus E
PLoS One; 2013; 8(11):e78641. PubMed ID: 24265703
[TBL] [Abstract][Full Text] [Related]
17. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
18. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
[TBL] [Abstract][Full Text] [Related]
19. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
Zheng H; Shao F; Martin S; Xu X; Deng CX
Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
